Kawasaki disease incidence in children and adolescents: an observational study in primary care

Abstract

Background

The incidence of Kawasaki disease after vaccination within the UK pre‐school National Immunisation Programme: an observational THIN database study

“…The outcome of interest was an episode of Kawasaki disease. Episodes of Kawasaki disease had previously been identified and validated in the same database population with the upper age of 20 years . In brief, the THIN database was searched for records with a Read code for Kawasaki disease or ‘kawasaki’ as unstructured text.…”

“…Episodes of Kawasaki disease had previously been identified and validated in the same database population with the upper age of 20 years. 6 In brief, the THIN database was searched for records with a Read code for Kawasaki disease or 'kawasaki' as unstructured text. Each record that was identified was reviewed by at least two of the authors and classified as a case or not against a case definition.…”

“…Seasonal variation in Kawasaki disease has also been reported in some studies 20 although no statistically significant trend was found in the recent UK study. 6 Seasonality should not have impacted the current study as preschool immunisations included in the study were given throughout the year based on the age of the child.…”

“…The highest incidence of Kawasaki disease is in the age group that receives most vaccinations within the pre‐school National Immunisation Programmes (NIPs). A recent UK study reported an annual incidence of 9.1 per 100 000 person years in those aged less than 5 years and 2.8 per 100 000 when aged under 20 years . Cases of Kawasaki disease have been reported immediately post‐childhood vaccination during clinical trials and in case reports although no causal association has been made .…”

“…A recent UK study reported an annual incidence of 9.1 per 100 000 person years in those aged less than 5 years and 2.8 per 100 000 when aged under 20 years. 6 Cases of Kawasaki disease have been reported immediately post-childhood vaccination during clinical trials and in case reports [7][8][9] although no causal association has been made. 9 In trials of RotaTeq (rotavirus vaccine, live, oral, pentavalent; Merck and Co. Inc., White House Station, NJ, USA), five cases were identified among vaccinated cases and one in the placebo group, crude relative risk 4.9 (95%CI 0.6, 239.1).…”